GLOW and KLOW are two multi-constituent research formulations in the Medicina Labs catalog. They differ
by one constituent: KLOW contains everything GLOW contains, plus KPV. This page sets out the composition difference and
explains why constituent-level research does not establish findings for either finished formulation.
Composition
| Constituent | GLOW | KLOW |
|---|---|---|
| GHK-Cu | Yes | Yes |
| BPC-157 | Yes | Yes |
| TB-500 | Yes | Yes |
| KPV | No | Yes |
Product pages: GLOW and KLOW. Total peptide content per vial differs
between the two formulations; the current figures are stated on each product page rather than repeated here, so that
this page cannot drift out of date.
What the fourth constituent is
KPV is the tripeptide lysine–proline–valine, corresponding to residues 11–13 of
α-melanocyte-stimulating hormone. PubChem lists it under CID 125672 (C16H30N4O4,
342.43 g/mol). It has been investigated in laboratory models of NF-κB and cytokine signalling, including PepT1-mediated uptake in epithelial cell models, separately from the other
three constituents.
Chemically the four constituents are very different materials: GHK-Cu is a copper-coordinated tripeptide, KPV a metal-free tripeptide, BPC-157 a 15-residue linear peptide and TB-500 the 43-residue synthetic thymosin beta-4 sequence. Those differences in size and composition are what an identity or purity method has to resolve in a multi-component preparation.
The evidence rule that matters here
Each of the four constituents has its own published literature. None of that literature examined GLOW or KLOW as
supplied. A finding reported for GHK-Cu in a fibroblast culture, or for BPC 157 in a rat tendon model, is a finding
about that single compound under those conditions — not about a formulation that also contains three other
peptides.
A PubMed search for these constituents in combination returns no study evaluating either finished formulation as supplied. Anyone designing
work with these materials should treat them as multi-component preparations whose combined behaviour has not been
characterised, and should not assume additivity between constituents.
Which page answers which question
If the question is chemical — what GHK-Cu actually is, and how the copper-bound complex differs from the free
tripeptide — see GHK vs GHK-Cu. If the question is about BPC 157’s
research literature, see the BPC-157 research overview.
Research use only
Both formulations are supplied strictly for in-vitro laboratory research. This page compares composition only. It does
not compare effectiveness, does not recommend one formulation over the other, and contains no preparation or use guidance.
References
Pickart L., Vasquez-Soltero J.M., Margolina A. (2015). Biomed Res Int, 2015:648108. PMID 26236730.
Chang C.H. et al. (2011). J Appl Physiol (1985), 110(3):774–80. PMID 21030672.
PubChem. Msh (11-13) [Lys-Pro-Val] — Compound Summary, CID 125672. National Library of Medicine.